Jean Jacques Bienaime is CEO at BIOMARIN PHARMACEUTICAL INC (BMRN). They have made 228 open-market trades across 8 companies since 2001, most recently 2026-08-17.
CIK 0001221590
38 open-market purchases totalling $2.8M since 2001, against 190 sales. Across 32 scored buys the stock is up 5.5% at ninety days, and 2.7 points ahead of the S&P over the same stretch.
33 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 18% | 55% | 69% |
| Avg Move | -10.3% | +1.7% | +5.5% |
| Alpha | -7.2% | +1.4% | +2.7% |
| Scored | 33 | 33 | 32 |
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 60% | 40% | 40% |
| Avg Move | -6.8% | +8.5% | +5.9% |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KROS | BUY | 2026-08-17 | 2026-08-19 | $10.27 | $10K | +3.4% | +4.2% | — |
| ASND | BUY | 2026-08-14 | 2026-08-18 | $246.33 | $493K | -3.1% | -6.6% | — |
| KROS | BUY | 2026-07-15 | 2026-07-17 | $10.61 | $11K | -8.6% | -3.3% | +2.5% |
| KROS | BUY | 2026-06-15 | 2026-06-17 | $10.19 | $10K | -2.1% | -2.3% | +2.6% |
| IMNM | SELL | 2026-06-05 | 2026-06-09 | $19.41 | $204K | +3.1% | +30.1% | +44.2% |
| IMNM | BUY | 2026-06-05 | 2026-06-09 | $19.45 | $204K | +3.1% | +30.1% | +44.2% |
| ASND | BUY | 2026-05-29 | 2026-06-01 | $223.12 | $112K | -2.2% | +21.7% | +19.6% |
| ASND | BUY | 2026-05-26 | 2026-05-27 | $237.80 | $95K | -12.9% | +10.4% | +7.1% |
| KROS | BUY | 2026-05-15 | 2026-05-19 | $10.58 | $11K | +8.3% | +6.3% | +4.4% |
| IMNM | BUY | 2026-05-15 | 2026-05-19 | $20.70 | $104K | +3.6% | -6.6% | +36.6% |
| KROS | BUY | 2026-04-15 | 2026-04-17 | $11.70 | $12K | -5.2% | -13.3% | -9.4% |
| IMNM | BUY | 2026-03-10 | 2026-03-12 | $21.84 | $44K | -4.8% | +6.5% | -14.4% |
| KROS | BUY | 2026-03-09 | 2026-03-11 | $11.21 | $22K | +0.0% | -0.3% | -10.4% |
| IMNM | BUY | 2025-06-03 | 2025-06-03 | $9.38 | $47K | -2.4% | -6.3% | -1.6% |
| IMNM | BUY | 2025-03-25 | 2025-03-26 | $7.78 | $61K | -22.6% | +10.5% | +17.4% |
| IMNM | BUY | 2025-03-24 | 2025-03-25 | $8.21 | $115K | -20.3% | +14.5% | +17.5% |
| IMNM | BUY | 2024-08-16 | 2024-08-19 | $13.94 | $98K | +4.8% | +6.6% | -35.1% |
| IMNM | BUY | 2024-05-21 | 2024-05-22 | $13.57 | $27K | -3.9% | -15.5% | +3.3% |
| BMRN | SELL · 10b5-1 | 2024-05-09 | 2024-05-13 | $81.38 | $3.3M | -6.0% | +4.7% | +10.3% |
| BMRN | SELL · 10b5-1 | 2024-04-11 | 2024-04-15 | $91.13 | $3.6M | -9.6% | -11.6% | -7.0% |
| BMRN | SELL | 2024-03-05 | 2024-03-07 | $86.11 | $172K | -0.7% | +1.6% | -7.3% |
| BMRN | SELL | 2024-02-27 | 2024-02-29 | $90.35 | $90K | -1.4% | +0.8% | -13.1% |
| BMRN | SELL · 10b5-1 | 2024-02-08 | 2024-02-12 | $89.03 | $2.7M | +4.7% | -2.7% | -7.6% |
| BMRN | SELL · 10b5-1 | 2024-01-09 | 2024-01-11 | $97.29 | $1.9M | -3.4% | -7.7% | -5.5% |
| BMRN | SELL · 10b5-1 | 2023-12-21 | 2023-12-22 | $93.99 | $940K | +0.1% | -2.4% | -12.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| NGSX |
| 21,748 |
| — |
| ITMN | 1,200 | — |
| Total | $30.9M |
Shares reported on the most recent Form 4, priced at the 2026-08-19 close. 2 holdings could not be priced and are excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Scored | 5 | 5 | 5 |